Abstract 15877: Use of the Multilayer Flow Modulator Stent as an Endovascular Therapeutic Alternative in the Treatment of High-Risk Thoraco-Abdominal Aneurysm
Background: Treatment of thoracoabdominal aneurysm (TAA) by either conventional surgery or covered stents is associated with a high rate of morbi-mortality. Implantation of flow modulating multilayer stents (MLS) is a recent alternative treatment which allows differed exclusion of the aneurysmal sac after thrombosis formation, without any risk of occluding an arterial branch arising from the TAA.
We report our preliminary experience in the treatment of TAA with MLS
Methods: Between April 2010 and April 2013, 4 patients included in the STRATO trial and presenting with high surgical risk TAA were treated by percutaneous implantation of MLS in the interventional cardiology department of the Hôpital Privé Claude Galien
Results: Four patients (75% female, mean age 81.7 yrs (range : 73-89), presenting with TAA (Crawford type II : 75% ; Type III: 25%) were treated by percutaneous MLS (100% transfemoral with 22-fr catheters)
Mean aneurysm diameter was 68.8 cm (min: 55.5 [[Unable to Display Character: –]] Max: 83.2). Procedural success was 100%; mean contrast volume: 184.75 ml (Min 120 [[Unable to Display Character: –]] Max: 250); total X-ray dose: 109.91 Gy.cm2 (min: 48.56 [[Unable to Display Character: –]] max: 200); percutaneous closure in 75%. A mean of 1.25 MLS were implanted per patient. Mean hospital stay was 8 days and CT-scan examination at discharge confirmed appropriate MLS position and absence of collateral branch occlusion. At 12 months’ follow-up, (clinical and CT-scan), survival rate was 100% with 100% collateral branch patency and a 9.5 % decrease in the size of the aneurysmal sac. Updated follow-up results will be available for the meeting.
Conclusion: Use of MLS seems a safe and efficient alternative to current treatment modalities of high-risk TAA, allowing differed exclusion of the aneurysmal sac and preservation of the collateral branches.
- © 2013 by American Heart Association, Inc.